Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Company Deals

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Drug

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Fineline Cube Jan 23, 2025

France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval in the European Union...

Company Deals

Eli Lilly and Merck Launch Consortium for Innovative Drug Manufacturing

Fineline Cube Jan 23, 2025

US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have...

Company Deals

Akeso Biopharma Receives Development Payment for PD-L1 Monoclonal Antibody

Fineline Cube Jan 22, 2025

China-based Akeso Biopharma (HKG: 9926) has announced receiving a drug collaboration development payment from compatriot...

Company Deals

Shanghai Bao Pharmaceuticals Launches IPO to Advance Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2025

China-based Shanghai Bao Pharmaceuticals Co., Ltd., a high-end biopharmaceuticals developer, has announced its initial public...

Company Deals

Degron Therapeutics Secures $20M Series A+ for Molecular Glue Drug Development

Fineline Cube Jan 22, 2025

China-based Degron Therapeutics, a specialist in molecular glue-based drugs, has reportedly raised over USD 20...

Company Drug

FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial

Fineline Cube Jan 22, 2025

France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US...

Company Drug

Johnson & Johnson’s Spravato Approved as Monotherapy for Major Depressive Disorder

Fineline Cube Jan 22, 2025

US-based Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Spravato (esketamine) CIII nasal...

Company Drug

CD Biopharma Initiates Phase I Trial for CD-001 in Advanced Solid Tumors

Fineline Cube Jan 22, 2025

Suzhou-based tumor immunotherapy specialist CD Biopharma has announced the first subject dosing of a Phase...

Company Medical Device

Kehua Bioengineering Gains NMPA Approval for Gene Polymorphism Detection Kits

Fineline Cube Jan 22, 2025

China-based Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022) has announced receiving marketing approvals from the...

Company Drug

Humanwell’s HWH340 Receives Clinical Approval for Prostate Cancer Treatment

Fineline Cube Jan 22, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug...

Company Deals

Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange

Fineline Cube Jan 22, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...

Company Medical Device

Acotec’s Vericor-S2 Coronary Microcatheter Approved by NMPA

Fineline Cube Jan 22, 2025

Acotec Scientific Holdings Ltd (HKG: 6669) has announced that its Vericor-S2 coronary microcatheter has received...

Company Deals

Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent

Fineline Cube Jan 22, 2025

Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...

Policy / Regulatory

Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism

Fineline Cube Jan 21, 2025

President Donald Trump has signed an executive order indicating the withdrawal of the United States...

Hospital

Douyin Gains Approval to Establish Hospital in Beijing’s Zhongguancun

Fineline Cube Jan 21, 2025

The Beijing Municipal Health Commission has approved Douyin, the Chinese short-form video hosting service owned...

Company Medical Device

NMPA Approves Synaptic Medical’s Cryoablation Device and Gene Methylation Detection Kit

Fineline Cube Jan 21, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval for two new medical devices:...

Company Drug

Huadong Medicine’s MediBeacon TGFR System Receives FDA Marketing Clearance

Fineline Cube Jan 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing clearance from the US...

Company Drug

MediLink’s YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced receiving another breakthrough therapy designation (BTD)...

Company Drug

Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes

Fineline Cube Jan 21, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment...

Company Drug

Arrowhead’s Plozasiran Accepted for FDA Review in Familial Chylomicronemia Syndrome

Fineline Cube Jan 21, 2025

US-based Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that the New Drug Application (NDA) for...

Posts pagination

1 … 245 246 247 … 688

Recent updates

  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
  • AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
  • Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
  • Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Company Medical Device

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.